Constitutive Androstane Receptor Isoform 3 (CAR3) Nuclear Receptor Assay Service

Precision in Every Step: Unleash CAR3's Potential with Our Expert Assay Services

Constitutive androstane receptor three (CAR3), is a variation of the nuclear receptor CAR, that is more often than not concerned with the regulation of drug metabolism and detoxification pathways within the liver. CAR3 is thought for its constitutive interest, which means it's miles lively even in the absence of a ligand. This makes it a vast target for analyzing drug-drug interactions, xenobiotic metabolism, and liver-precise gene regulation. Nuclear receptor assay services are designed to observe and compare the pastime, binding affinity, and functionality of nuclear receptors. These assays may be used to screen for ability drug applicants, look into receptor-ligand interactions, and understand the molecular mechanisms underlying numerous sicknesses.

The CAR3 nuclear receptor assay is essential in the study of absorption, distribution, metabolism, and excretion (ADME) techniques. Creative Biolabs is at the forefront of biotechnological innovation, offering specialized assay offerings to boost drug discovery and development. Our CAR3 nuclear receptor assay is meticulously designed to offer complete insights into the activity and regulation of the CAR3 receptor. By leveraging advanced technologies and a crew of professional scientists, Creative Biolabs supplies wonderful, reproducible facts that support the identification and optimization of novel therapeutics.

Our service is designed to provide unparalleled precision and reliability, ensuring that researchers and pharmaceutical developers receive the highest quality data for their projects. With a team of dedicated scientists and state-of-the-art facilities, Creative Biolabs is committed to advancing the field of drug discovery and development through innovative and customized assay solutions.

Our CAR3 nuclear receptor assay service features a robust and reliable methodology. We utilize human CAR3 receptors in a functional, cell-based assay format to evaluate both agonist and antagonist activities. The detection of functional responses is quantified through IC50 measurements, providing detailed insights into the potency and efficacy of test compounds.

Receptor Assay Type Subtype Functional Mode Detection
Human CAR3 Functional Cell-based Agonist IC50
Functional Cell-based Antagonist IC50

Technical Workflow

  1. Cell Line Preparation
    • Cell Culture: Cells expressing the human CAR3 receptor are cultured under optimal conditions.
    • Transfection: Cells are transfected with a reporter gene construct designed to provide measurable outputs upon receptor activation.
  2. Assay Setup
    • Seeding: Transfected cells are seeded into 96-well or 384-well plates to allow for high-throughput screening.
    • Compound Preparation: Test compounds, including both potential agonists and antagonists, are prepared at varying concentrations for dose-response analysis.
  3. Compound Treatment
    • Agonist Assay: Cells are treated with test compounds to assess agonist activity, measuring the extent to which each compound activates the CAR3 receptor.
    • Antagonist Assay: Cells are pre-treated with known CAR3 agonists followed by test compounds to assess the antagonist activity, determining how effectively each compound inhibits receptor activation.
  4. Incubation
    • Cells are incubated with the test compounds for a predetermined period to allow for adequate interaction and receptor activation or inhibition.
  5. Detection and Measurement
    • Reporter Gene Readout: After incubation, the functional response is measured using a reporter gene assay. This typically involves the detection of luminescent or fluorescent signals proportional to receptor activity.
    • IC50 Calculation: Data from dose-response curves are analyzed to calculate IC50 values, indicating the concentration at which each compound achieves half-maximal inhibition (for antagonists) or activation (for agonists).

Published Data

This study features a detailed cell-based quantitative high-throughput screening (qHTS) assay optimization and the identification of human CAR agonists, as depicted in Figure 1. This figure illustrates the optimization manner of the cellular-based totally qHTS assay, highlighting key steps such as cell line selection, transfection performance, and assay validation. Additionally, it demonstrates the identity of potential hCAR agonists from a large compound library. The parent underscores the importance of optimizing assay conditions to attain high sensitivity and specificity, facilitating the accurate detection of hCAR modulators.

Fig.1 Constitutive androstane receptor agonist identification. (Lynch, Caitlin, et al., 2017)Fig.1 Cell-based qHTS assay optimization and hCAR agonist identification.1

Applications

Advantages

At Creative Biolabs, CAR3 nuclear receptor assay stands out as a premier solution for researchers and pharmaceutical developers aiming to advance their drug discovery and development projects. Our expertise, advanced technology, and commitment to quality ensure that you receive precise, reliable, and actionable data. If you are looking to gain deeper insights into the metabolism, safety, and efficacy of your drug candidates through comprehensive CAR3 nuclear receptor assays, feel free to contact Creative Biolabs today.

Reference

  1. Lynch, Caitlin, et al. "Quantitative high-throughput identification of drugs as modulators of human constitutive androstane receptor." Scientific reports 5.1 (2015): 10405.

For Research Use Only | Not For Clinical Use

Online Inquiry
Copyright © 2024 Creative Biolabs. All Rights Reserved.